DEVELOPING
NOTABLE65
REGULATORYLimited grounding
Hims & Hers, Novo Nordisk: FDA GLP-1 Compounding Ruling May Actually Favor Hims (NYSE:NVO) - Seeking Alpha
Analysis
An FDA GLP-1 compounding ruling framed as favorable to Hims complicates Novo's effort to shut down compounded semaglutide channels.
- Headline frames FDA GLP-1 compounding ruling as potentially favoring Hims & Hers
Novo Nordisk News2d
Read